In a recent study using human hepatoma cell lines, CysLT antagonists (pranlukast and montelukast) inhibited ADAM9 activity and upregulated level of membrane-bound MHC class I-related chain A (mMICA), which might facilitate natural killer cell-mediated cytotoxicity, suggesting the potential of using leukotriene receptor antagonists along with regorafenib in the treatment of hepatoma [63]. This evidence concerns the gene ADAM9 and hepatocellular carcinoma.